Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 19;10(1):35.
doi: 10.1186/s40352-022-00199-1.

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study

Affiliations

The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study

Elizabeth C Saunders et al. Health Justice. .

Abstract

While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed protocols to sustain healthcare delivery while reducing risk of COVID-19 transmission. This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. In December 2020, carceral sites (n = 6; median pre-COVID 2020 monthly census = 3468 people) and CTPs (n = 7; median pre-COVID 2020 monthly census = 550 patients) participating in EXIT-CJS completed a cross-sectional web-based survey. The survey assessed changes pre- (January-March 2020) and post- (April-September 2020) COVID-19 in OUD treatment, telemedicine use, re-entry supports and referral practices. Compared to January-March 2020, half of carceral sites (n = 3) increased the total number of persons initiating medication for opioid use disorder (MOUD) from April-September 2020, while a third (n = 2) decreased the number of persons initiated. Most CTPs (n = 4) reported a decrease in the number of new admissions from April-September 2020, with two programs stopping or pausing MOUD programs due to COVID-19. All carceral sites with pre-COVID telemedicine use (n = 5) increased or maintained telemedicine use, and all CTPs providing MOUD (n = 6) increased telemedicine use. While expansion of telemedicine services supported MOUD service delivery, the majority of sites experienced challenges providing community support post-release, including referrals to housing, employment, and transportation services. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to continue delivery of treatment for OUD. Expansion of telemedicine services was critical to support MOUD service delivery. Despite these innovations, sites experienced challenges providing reintegration supports for persons in the community. Pre-COVID strategies for identifying and engaging individuals while incarcerated may be less effective since the pandemic. In addition to expanding research on the most effective telemedicine practices for carceral settings, research exploring strategies to expand housing and employment support during reintegration are critical.

Keywords: Buprenorphine; COVID-19; Carceral settings; Medication for opioid use disorder (MOUD); Naltrexone; Opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

Drs. Lee, Springer, Farabee, and Waddell have received in-kind study drug from Indivior and Alkermes for other federally funded trials. Dr. Springer has provided scientific consultation for Alkermes. Dr. Schwartz has provided consultation for Verily Life Sciences. Dr. Marsch is affiliated with Pear Therapeutics, Inc. and Square2 Systems, Inc. Dr. Gryczynski is part owner of COG Analytics. Drs. Gryczynski, Lee, and Monico have received research funding from Indivior for conduct of a health survey study.

Similar articles

References

    1. 117th Congress . H.R.955 - Medicaid reentry act of 2021. 2021.
    1. 117th Congress . Humane correctional health care act. 2021.
    1. Baillargeon J, Polychronopoulou E, Kuo YF, Raji MA. The impact of substance use disorder on COVID-19 outcomes. Psychiatric Services. 2021;72(5):578–581. doi: 10.1176/appi.ps.202000534. - DOI - PMC - PubMed
    1. Bandara S, Kennedy-Hendricks A, Merritt S, Barry CL, Saloner B. Early effects of COVID-19 on programs providing medications for opioid use disorder in jails and prisons. Journal of Addiction Medicine. 2020;14(5):e257–e260. doi: 10.1097/adm.0000000000000718. - DOI - PubMed
    1. Belenko S, Hiller M, Hamilton L. Treating substance use disorders in the criminal justice system. Current Psychiatry Reports. 2013;15(11):414. doi: 10.1007/s11920-013-0414-z. - DOI - PMC - PubMed

LinkOut - more resources

-